Haiyun Xiong

Dr. Haiyun Xiong


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
JLJun Li
Jun Li
DJDonggen Jiang
Donggen Jiang
QZQian Zhang
Qian Zhang
SPShubin Peng
Shubin Peng
GLGuolong Liao
Guolong Liao
JPJun Pang
Jun Pang
Objective: Renal cell carcinoma (RCC) displays an increasing incidence and mortality rate worldwide in recent years. More and more evidence demonstrated microRNAs function as positive or negative regulatory factors in many cancers, while the role of miR-301a in RCC is still unclear. Material and Methods: The expression and clinical significance of miR-301a were assessed via bioinformatic software on open microarray datasets of the Cancer Genome Atlas (TCGA) and then confirmed by quantitative real-time PCR (qRT-PCR) in RCC cell lines. Loss of function assays were performed in RCC cell lines both in vitro and in vivo. Cell Counting Kit-8 (CCK-8), flow cytometry, luciferase reporter assays, Western blotting, and immunohistochemistry were employed to explore the mechanisms of the effect of miR-301a on RCC. Results: By analyzing RCC clinical specimens and cell lines, we found a uniform increased miR-301a in expression in comparison with normal renal tissue or normal human proximal tubule epithelial cell line (HK-2). In addition, miR-301a upregulation correlated advanced stage and poor prognosis of clear cell RCC (ccRCC). Anti-miR-301a could inhibit growth and cell cycle G1/S transition in RCC cell lines. Moreover, we found that PTEN was identified as a direct target of miR-301a that might partially interrupt miR-301a-induced G1/S transition. Importantly, nude-mouse models revealed that knockdown of miR-301a delayed tumor growth. Conclusion: These results indicate that miR-301a functions as a tumor-promoting miRNA through regulating PTEN expression, representing a novel therapeutic target for RCC.

1 January 2024 in Journal of Cancer
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
LYLu Yu
Lu Yu
ZCzhiguang chang
zhiguang chang
HXHaiyun Xiong
Haiyun Xiong
Bladder instillation therapy is a common treatment for superficial or nonmuscle invasive bladder cancer. After surgery or reresection, chemotherapy drugs (epirubicin) or medications such as Bacillus Calmette-Guérin (BCG) are used for bladder instillation therapy, which can reduce the risk of bladder cancer recurrence and progression. However, the specific mechanism by which BCG stimulates the antitumor response has not been thoroughly elucidated. Additionally, although BCG immunotherapy is effective, it is difficult to predict which patients will have a positive response. In this study, we explored the BCG-induced immune response and found that high levels of Fms-related receptor tyrosine kinase 3 ligand (FLT3LG) were expressed after BCG treatment. This FLT3LG can directly act on CD8+ T cells and promote their proliferation and activation. The use of FLT3 inhibitors can neutralize the antitumor effects of BCG. In vitro experiments showed that FLT3LG can synergize with T-cell receptor activators to promote the activation of tumor-derived T cells. This study partially elucidates the mechanism of CD8+ T-cell activation in BCG immunotherapy and provides a theoretical basis for optimizing BCG instillation therapy in bladder cancer

24 August 2026 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
SZShiqiang Zhang
Shiqiang Zhang
YSYiyu Sheng
Yiyu Sheng
YWYiran Wang
Yiran Wang
SZSikun Zhu
Sikun Zhu
HXHaiyun Xiong
Haiyun Xiong

26 February 2026 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
YSYiyu Sheng
Yiyu Sheng
LFLonglong Fan
Longlong Fan
SZSikun Zhu
Sikun Zhu
YWYiran Wang
Yiran Wang
ZSZhang Shiqiang
Zhang Shiqiang
HXHaiyun Xiong
Haiyun Xiong

3 March 2026 in Current Urology
Verified
Journal Article
Open access
SZShiqiang Zhang
Shiqiang Zhang
SZSikun Zhu
Sikun Zhu
LLLujing Li
Lujing Li
YSYiyu Sheng
Yiyu Sheng
JLJun Li
Jun Li
HXHaiyun Xiong
Haiyun Xiong